COPD, a term that covers a variety of conditions that affect the ability to breathe, is now a global phenomenon. The World Health Organization estimates that COPD will be the third leading cause of death in 2030. It affects approximately 210 million people around the world.

23 million Americans suffer from COPD. This includes emphysema, chronic obstructive lung disease, and asthma. The symptoms include chronic cough, shortness of breath and increased sputum production. As the disease progresses slowly, most people diagnosed with COPD are aged 40 or older. Doctors agree that COPD is still under-diagnosed despite its high prevalence.

COPD can cause severe breathing problems, whether it is caused by smoking, occupational chemicals, or indoor and outdoor air pollution. It can make it nearly impossible to do everyday tasks like cooking or walking. Although there is no cure for COPD (or any other condition), oxygen therapy can be used to help patients regain their daily activities.

There is a huge demand for oxygen therapy technology because of the large number of COPD patients around the globe. Ingen Technologies has developed the Oxyview pneumatic flow meter, which aids nurses and caretakers in diagnosing oxygen shortages. This flow meter is unique because it can be used in any location and is immune to humidity, vibration, and altitude. This gauge saves lives and prevents unnecessary visits to the medical staff.

“The doctors like our products because they cut down on mishaps, which should add a confidence level to the medical industry,” says Ingen CEO Chris Wirth.

The Oxyview is gaining international attention. Ingen has signed distributor agreements in Saudi Arabia and Taiwan. Ingen is still in negotiations with Indian companies and has plans to expand into Europe.

For more information, please visit